Vor Bio Announced Successful Primary Engraftment Of Trem-cel In First Five Acute Myeloid Leukemia Patients
Portfolio Pulse from Charles Gross
Vor Bio (NASDAQ:VOR) announced successful primary engraftment of trem-cel in the first five acute myeloid leukemia patients in its Phase 1/2a VBP101 study. The data was presented at the European Hematology Association 2023 Congress in Frankfurt, Germany.
June 09, 2023 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vor Bio's successful primary engraftment of trem-cel in first five AML patients in Phase 1/2a VBP101 study may positively impact its stock price.
The successful primary engraftment of trem-cel in the first five AML patients in Vor Bio's Phase 1/2a VBP101 study indicates positive progress in the company's clinical trials. This news may attract investor interest and lead to an increase in Vor Bio's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100